ImmunityBio tries again in papillary bladder cancer
And the company says it won’t need to carry out another trial.
Epkinly fails its first confirmatory test
And that could affect the drug's third-line accelerated approval.
M&A analysis: bolt-ons for J&J and Bristol
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
AstraZeneca goes all-in on AbelZeta’s Car
A fresh licensing deal tidies up years of work between the two companies.
Pfizer trims its pan-KRAS efforts
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
Black Diamond advances in brain cancer
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Innovent gives another cytokine a shot
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
ArriVent moves to take on Rybrevant
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
J&J claims another second-line Tecvayli win
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
